Trial Profile

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tivantinib (Primary) ; Cetuximab; Docetaxel; Erlotinib; Gemcitabine; Irinotecan; Pemetrexed; Sorafenib
Indications Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cancer; Solid tumours
Focus Therapeutic Use
Sponsors ArQule

Most Recent Events

04 Jun 2020 Status changed from active, no longer recruiting to completed.
15 Jan 2019 Planned End Date changed from 1 Feb 2019 to 1 Apr 2019.
15 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com